Total Voting Rights

RNS Number : 8707U
Allergy Therapeutics PLC
01 July 2009
 



Wednesday 1 July 2009



Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")


Appointment of Directors, Directors Holdings and Total Voting Rights


AIM Rule Disclosure- Schedule 2(g)


Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that further to the announcement made by the Company on 12 June 2009, Alejandro Esteban Weinstein Manieu (51) and Manuel Llobet (45) were today appointed as directors of the Company.


In accordance with Rule 17 of the AIM Rules, the following information can be disclosed regarding Alejandro Weinstein and Manuel Llobet:


Alejandro Weinstein


Current directorships and partnerships

Past directorships and partnerships within the last five years

Genomika Foundation


Laboratorios Recalcine S.A.


Biomedical Research Consortium



Manuel Llobet


Current directorships and partnerships

Past directorships and partnerships within the last five years


Drokasa Peru S.A.


Gynopharm S.A. (Costa Rica) 


Gynopharm S.A. (Colombia)


Laboratorios Elea México S.A. de C.V.


Servicios Elche S.A. de C.V.


Laboratorios Atlas


Gynopharm de Venezuela C.A.


Farmindustria S.A.


There is no further information to be disclosed under Schedule 2(g) of the AIM Rules for Companies.


Directors' holdings


After Admission, the interests of the Directors and the percentage of the Company's issued share capital which they represent are as follows:



Number of Ordinary Shares

% of Share Capital after Admission

Keith I Carter

3,192,669

1.21%

Ignace R Goethals

4,897,912

1.86%

Ian Postlethwaite

0

0.00%

Tom Holdich

0

0.00%

Christian Gratz

510,658

0.19%

Stephen R Smith

756,513

0.29%

Virinder Nohria

5,211

0.00%

Alejandro Weinstein*

0

0.00%

Manuel Llobet**

0

0.00%


*Alejandro Weinstein is a beneficiary of Azure Ventures Limited, which is interested in 104,166,666 shares, 39.46% of the Company

** Manuel Llobet is a beneficiary of Wild Indigo S.A, which is interested in 3,125,000 shares, 1.18% of the Company



Total Voting Rights Following Admission


The Company's issued voting share capital is 263,998,551 ordinary shares of 0.1p each.


For further information


Allergy Therapeutics

+44 (0) 1903 845 820

Keith Carter, Chief Executive


www.allergytherapeutics.com




Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw




Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley





This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREAKXFEDSNEEE
UK 100

Latest directors dealings